FI118688B - Hepatit-C-virustyperna 4,5 och 6 - Google Patents

Hepatit-C-virustyperna 4,5 och 6 Download PDF

Info

Publication number
FI118688B
FI118688B FI955224A FI955224A FI118688B FI 118688 B FI118688 B FI 118688B FI 955224 A FI955224 A FI 955224A FI 955224 A FI955224 A FI 955224A FI 118688 B FI118688 B FI 118688B
Authority
FI
Finland
Prior art keywords
hcv
peptide
type
antigenic
peptides
Prior art date
Application number
FI955224A
Other languages
English (en)
Finnish (fi)
Other versions
FI955224A0 (sv
FI955224A (sv
Inventor
Peter Simmonds
Peng Lee Yap
Ian Hugo Pike
Original Assignee
Common Services Agency
Murex Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939309237A external-priority patent/GB9309237D0/en
Priority claimed from GB9400263A external-priority patent/GB9400263D0/en
Application filed by Common Services Agency, Murex Diagnostics Ltd filed Critical Common Services Agency
Publication of FI955224A0 publication Critical patent/FI955224A0/sv
Publication of FI955224A publication Critical patent/FI955224A/sv
Application granted granted Critical
Publication of FI118688B publication Critical patent/FI118688B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)

Claims (30)

1. HCV-peptid med en antigenisk NS4-sekvens som kan vara nägon av följande:
2. AAGCCTGCTGTTGTCCCTGATCGCGAGATCTTATACCAGCAGTTTGACGAGATG GAGTGTTCCAAACACCTTCCACTAGTCGAGCACGGGTTGCAACTTGCTGAGCAATTC GAGTGCTCGACCTCGCTCCCCTATATGGACGAGGCACGTGCTATTGCCGGGCAATTC . GAGTGCTCTAGGCACATCCCCTACCTCGCTGAGGGCCAGCAGATCGCCGAACAGTTC ·«·
2. Peptid enligt patentkrav 1, som är bunden till kaman av en multiantigenpeptid.
3. Peptid enligt patentkrav 2, med en sekvens som kan vara nägon av följande:
4. Peptid enligt patentkrav 1, som är fusionerad med en annan peptid för att bilda en fusionspeptid. ···
5. Peptid enligt patentkrav 4 fusionerad med en an- !.**i 25 nan peptid, som kan vara en sekvens som kan kodas till β- e · :.1'i galaktosidas, glutation-S-transferas, trpE eller polyhed- Ii ί rin.
··· · • 6. Peptid enligt nägot av de föregäende patentkra- Mt * .***· ven, som är märkt. * · 1 '
5 HCV typ 4 QPAVIPDREVLYQQFDEM HCV typ 4 ECSKHLPLVEHGLQLAEQF HCV typ 5 RPAIIPDREVLYQQFDKM HCV typ 5 ECSTSLPYMDEARAIAGQF HCV typ 6 KPAWPDREILYQQFDEM 10 HCV typ 6 ECSRHIPYLAEGQQIAEQF.
7. Antikropp mot en antigenisk peptid enligt nägot ..t av de föregäende patentkra ven.
* ·· *... 8. Anordning för immunologisk bestämning, som om- • · ·“ fattar ett fast substrat, vid vilket en antigenisk peptid • · ϊ#·.· enligt nägot av patentkraven 1 - 6 är fäst. *···· * ♦ • · · • · · » 118688
9. Anordning enligt patentkrav 8, där en blandning av antigeniska peptider av HCV typ 4, typ 5 eller typ 6 är fästa vid det fasta substratet.
10. Anordning enligt patentkrav 8, där en blandning 5 av antigeniska peptider av HCV typ 4, typ 5 och typ 6 är fästa vid det fasta substratet.
11. Anordning enligt patentkrav 8, 9 eller 10, där blandningen dessutom omfattar en eller flera antigeniska NS4-peptider av HCV typerna 1-3.
12. Anordning enligt patentkrav 11, där blandningen är en blandning av antigeniska peptider av HCV typerna 1, 2, 3, 4, 5 och 6.
13. Anordning enligt patentkrav 8 för HCV-typifie-ring, kännetecknad av att den omfattar ett fast sub- 15 strat med en serie punkter som innehäller antigeniska peptider av typen HCV-4, HCV-5 och respektive HCV-6.
14. Anordning enligt nägot av patentkraven 8-13, kännetecknad av att det fasta substratet omfattar en serie punkter, varvid en antigenisk peptid eller en bland- 20 ning av antigeniska peptider är fästa vid respektive punkt.
15. Anordning enligt patentkrav 14, kännetecknad av att respektive punkt innehäller en blandning icke fästa antigeniska, blockerande HCV-peptider, varvid bland- *;**. ningen vid varje punkt saknar en peptid av den HCV-typ, som • · · *· " 25 ifrägavarande punkt är avsedd att detektera.
*.**! 16. Anordning enligt nägot av patentkraven 13 - 15 · · för detektering av HCV typerna 1 - 6. • · jt; j
17. Immunologiskt testkit, kännetecknat av att det omfattar en anordning enligt patentkrav 14 och en serie 30 lösningar, varav var och en omfattar en blandning av anti- j·.^ geniska, blockerande HCV-peptider, som saknar den peptid av .··. HCV-typ, som ifrägavarande punkt är avsedd att detektera. • · "1
18. Immunologiskt testkit enligt patentkrav 17, :.**ϊ kännetecknat av att anordningen för immunologisk be- *ί**ί 35 stämning omfattar ett fast substrat med en serie punkter, *\\ varvid en blandning av antigeniska peptider av HCV-typ 1, • · · 118688 2, 3, 4, 5 och 6 är fast vid varje punkt; och en serie av sex lösningar, varvid var och en omfattar en blandning av olika antigeniska, blockerande HCV-peptider, som har valts bland antigeniska peptider av HCV typ 1, 2, 3, 4, 5 och 6, 5 och de sex lösningarna saknar pä motsvarande sätt en anti-genisk peptid av den typ, som en bestämd punkt vid vilken ifrägavarande lösning appliceras, är avsedd att detektera.
15 HCV typ 4 [H2N-QPAVIPDREVLYQQFDEM]8K4K2K-COOH HCV typ 4 [H2N-ECSKHLPLVEHGLQLAEQF] 8K4K2K-COOH HCV typ 5 [H2N-RPAIIPDREVLYQQFDKM]8K4K2K-COOH HCV typ 5 [H2N-ECSTSLPYMDEARAIAGQF] 8K4K2K-COOH HCV typ 6 [H2N-KPAWPDREILYQQFDEM] 8K4K2K-COOH 20 HCV typ 6 [H2N-ECSRHIPYLAEGQQIAEQF] 8K4K2K-COOH där K4K2K är kärnan i en multiantigenpeptid.
19. Anordning för immunologisk bestämning, som omfattar ett fast substrat, vid vilken en antikropp enligt 10 patentkrav 6 är fäst.
20. Förfarande för in vitro-testning av ett prov för HCV-antikroppar, kännetecknat av att en immunolo-gisk bestämning utförs med hjälp av en antigenisk peptid enligt nägot av patentkraven 1-6 och ett eventuellt bills dat antikropp-antigenkomplex detekteras.
21. Förfarande enligt patentkrav 20, kännetecknat av att den antigeniska peptiden är fäst vid ett fast substrat, och den i provet eventuellt befintliga HCV-anti-kroppen som är avsedd att detekteras binder sig tili pepti- 2. den.
22. Förfarande enligt patentkrav 21, kännetecknat av att blandningen av antigeniska peptider är fäst vid , det fasta substratet.
**· ·;·· 23. Förfarande enligt patentkrav 22, känneteck- • · * " 25 nat av att blandningen är en blandning av antigeniska pep- • · tider av HCV typ 1, 2, 3, 4, 5 och 6.
« · !,· : 24. Förfarande enligt nägot av patentkraven 21 - 23, ίϊ*: kännetecknat av att blandningen av antigeniska, blocke- :*·*: rande HCV-peptider leds tili den vid det fasta substratet 30 fästa antigeniska peptiden tillsammans med provet, vilken ··, blandning av blockerande peptider saknar en peptid av den • · · \,,t HCV-typ som man avser att detektera.
• « *!* 25. Förfarande enligt patentkrav 24, känneteck- • · nat av att det fasta substratet omfattar en serie punkter, *ί**ί 35 varvid en blandning av antigeniska peptider är fäst vid .·[·, varje punkt; och blandningen av antigeniska, blockerande f · • m * 4) 118688 HCV-peptider, sorti förs till det fasta substratet, saknar peptider av den HCV-typ, som en bestämd punkt är avsedd att detektera.
26. Förfarande enligt patentkrav 25, känneteck-5 nat av att substratet omfattar en serie av sex punkter, varvid en blandning av antigeniska peptider av HCV typ 1, 2, 3, 4, 5 och 6 är fäst vid varje punkt; och blandningen av antigeniska, blockerande peptider, som tillförs tili re-spektive punkt, saknar peptider av den HCV-typ, som punkten 10 är avsedd att detektera.
27. Förfarande enligt patentkrav 20, känneteck-nat av att i provet eventuellt förekommande HCV-anti-kroppar fäs att fastna vid substratet, varefter en antige-nisk peptid enligt patentkrav 6 tillförs för detektering av 15 fastnade HCV-antikroppar.
28. Isolerad HCV-polynukleotid med en NS4-sekvens, som kan vara nägon av följande sekvenser: CAGCCTGCTGTTATCCCTGACCGCGAGGTGCTCTACCAGCAGTTCGACGAAATG AGACCTGCCATCATTCCCGATAGAGAGGTGTTGTACCAGCAATTTGATAAGATG
29. Polynukloetid som kodar för en peptid enligt I · · *· ** 25 patentkrav 1.
• · *.'·! 30. Förfarande för in vitro-testning av HCV i ett • » ·.· · prov, kännetecknat av att en i provet eventuellt före- ]j*: kommande HCV-polynukleotid kopieras genom omvänd tran- skriptas, dupliceras genom en polymeraskedjereaktion och 30 den duplicerade HCV-polynukleotiden detekteras genom att :*. som sond använda en polynukleotid enligt patentkravet 28 • ·· ]···. eller 29. « · ··· • · • · · * ·· • · «···· • · • • 9 9 · • · · 9 9 m 99999 9 ·
FI955224A 1993-05-05 1995-11-01 Hepatit-C-virustyperna 4,5 och 6 FI118688B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9309237 1993-05-05
GB939309237A GB9309237D0 (en) 1993-05-05 1993-05-05 Hepatitis-c virus type 4 and 6
GB9400263 1994-01-07
GB9400263A GB9400263D0 (en) 1994-01-07 1994-01-07 Hepatitis-C virus type 4,5 & 6
PCT/GB1994/000957 WO1994025602A1 (en) 1993-05-05 1994-05-05 Hepatitis-c virus type 4, 5 and 6
GB9400957 1994-05-05

Publications (3)

Publication Number Publication Date
FI955224A0 FI955224A0 (sv) 1995-11-01
FI955224A FI955224A (sv) 1995-12-20
FI118688B true FI118688B (sv) 2008-02-15

Family

ID=26302858

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955224A FI118688B (sv) 1993-05-05 1995-11-01 Hepatit-C-virustyperna 4,5 och 6

Country Status (9)

Country Link
US (4) US6881821B2 (sv)
EP (1) EP0698101B1 (sv)
JP (3) JP3751315B2 (sv)
AT (1) ATE281526T1 (sv)
AU (1) AU695259B2 (sv)
DE (1) DE69434116T2 (sv)
ES (1) ES2231773T3 (sv)
FI (1) FI118688B (sv)
WO (1) WO1994025602A1 (sv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695259B2 (en) * 1993-05-05 1998-08-13 Common Services Agency Hepatitis-C virus type 4, 5 and 6
WO1994027153A1 (en) 1993-05-10 1994-11-24 Chiron Corporation Methods of typing hepatitis c virus and reagents for use therein
GB2294690B (en) * 1994-11-01 1998-10-28 United Biomedical Inc Peptides effective for diagnosis and detection of hepatitis C infection
WO1997040147A1 (en) 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Antigenically reactive regions of the hepatitis a virus polyprotein
CA2303123C (en) * 1997-09-22 2006-04-11 Chiron Corporation Method for detecting antibodies in a sample
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
US7326536B2 (en) * 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
PT2014671E (pt) * 2002-03-11 2010-06-16 Lab 21 Ltd Métodos e composições para identificar e caracterizar a hepatite c
CA2552949C (en) * 2004-01-07 2012-10-02 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
WO2005118626A2 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
EP2121991A2 (en) * 2006-10-20 2009-11-25 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
CA2580589C (en) * 2006-12-19 2016-08-09 Fio Corporation Microfluidic detection system
WO2008119184A1 (en) 2007-04-02 2008-10-09 Fio Corporation System and method of deconvolving multiplexed fluorescence spectral signals generated by quantum dot optical coding technology
CN101821322B (zh) 2007-06-22 2012-12-05 Fio公司 制备量子点掺杂的聚合物微珠的系统和方法
US8551786B2 (en) * 2007-07-09 2013-10-08 Fio Corporation Systems and methods for enhancing fluorescent detection of target molecules in a test sample
CA2761176C (en) * 2007-07-23 2012-07-31 Fio Corporation A method and system for collating, storing, analyzing and enabling access to collected and analyzed data associated with biological and environmental test subjects
US8551763B2 (en) * 2007-10-12 2013-10-08 Fio Corporation Flow focusing method and system for forming concentrated volumes of microbeads, and microbeads formed further thereto
BRPI0915514A2 (pt) 2008-06-25 2016-01-26 Fio Corp sistema e método de infra-estrutura de alerta de ameaça biológica, dispositivo de alerta de ameaça biológica e um método para alertar um usuário do mesmo
CN102165321B (zh) 2008-08-29 2016-03-16 Fio公司 用于检测生物和环境检测样品的一次性手持式诊断检测设备和相关系统与方法
EP2387721A4 (en) 2009-01-13 2014-05-14 Fio Corp PORTABLE DIAGNOSTIC TEST DEVICE AND METHOD FOR USE WITH AN ELECTRONIC DEVICE AND TEST CARTRIDGE FOR QUICK DIAGNOSTIC TESTS
WO2014074620A1 (en) * 2012-11-07 2014-05-15 Gilead Sciences, Inc. Hcv genotype 6 replicons

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU216017B (hu) * 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
JP3114731B2 (ja) * 1990-08-14 2000-12-04 国立感染症研究所長 Ｃ型肝炎ウイルス抗体検出用ペプチド抗原及びその使用方法
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
ES2065863T3 (es) * 1991-11-21 2003-09-01 Common Services Agency Analisis para la deteccion de virus de la hepatitis c.
CA2139100C (en) * 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
AU695259B2 (en) * 1993-05-05 1998-08-13 Common Services Agency Hepatitis-C virus type 4, 5 and 6
EP0729973A4 (en) 1993-10-29 1998-12-30 Srl Inc AN ANTIQUE PEPTIDE COMPOUND AND IMMUNOASSAY PROCEDURE

Also Published As

Publication number Publication date
FI955224A0 (sv) 1995-11-01
DE69434116T2 (de) 2005-10-27
US20050032047A1 (en) 2005-02-10
US7728121B2 (en) 2010-06-01
US7198892B2 (en) 2007-04-03
JPH09500009A (ja) 1997-01-07
EP0698101A1 (en) 1996-02-28
AU6579794A (en) 1994-11-21
JP3895747B2 (ja) 2007-03-22
US20080262211A1 (en) 2008-10-23
JP4171508B2 (ja) 2008-10-22
WO1994025602A1 (en) 1994-11-10
US20070160630A1 (en) 2007-07-12
US7402315B2 (en) 2008-07-22
US6881821B2 (en) 2005-04-19
FI955224A (sv) 1995-12-20
JP2007075119A (ja) 2007-03-29
AU695259B2 (en) 1998-08-13
ES2231773T3 (es) 2005-05-16
DE69434116D1 (en) 2004-12-09
US20050221296A1 (en) 2005-10-06
JP2005124585A (ja) 2005-05-19
EP0698101B1 (en) 2004-11-03
JP3751315B2 (ja) 2006-03-01
ATE281526T1 (de) 2004-11-15

Similar Documents

Publication Publication Date Title
FI118688B (sv) Hepatit-C-virustyperna 4,5 och 6
JP3171793B2 (ja) Ｎａｎｂｖの診断用薬
FI113967B (sv) Hepatitis-C-virustest
EP0698216B2 (en) Methods of typing hepatitis c virus and reagents for use therein
CA2162134C (en) Hepatitis-c virus type 4,5 and 6
SI8812138A (sl) Nanbv diagnostiki in cepiva

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118688

Country of ref document: FI

MA Patent expired